Mylan files lawsuit against FDA

Earlier, Ranbaxy has got exclusive rights for selling the drug from Pfizer, under a settlement agreement signed between the companies which provides Ranbaxy with the 180 days of marketing exclusivity.

Ranbaxy was the first company who has applied to sell the cheaper version of Lipitor.

Mylan wants a court to force the FDA to say publicly whether Ranbaxy’s application "is tainted by Ranbaxy’s misconduct" and that therefore the application must be denied and the 180-day reward voided, Bloomberg reported.

A victory for Mylan will let it enter the market in June, when some of the Lipitor patents expire.